WARN : Please note that some of the values may not be in base currency

Fundamental Analysis of BiondVax Pharmaceuticals Ltd. - Growth / Value Index


BVXV - Valuation Highlights

Valuation Analysis

   Tsr Value Index - Very Poor Score of 5.00
   Price to Book Ratio of 1099.29 suggesting that it is very expensive
   Book value is negative
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning 140.98 -175.32 -47845.78 %
Price to Book 1099.29 -577.35 -92254.30 % -0.646
Price to Sales 348.44 0 0 %
Enterprise Value to EBITDA Multiple -1.01 -97.39 -10479.80 %


BVXV - Profitability Highlights

Profitability Analysis

   During the past twelve months, the company has given a strong Return On Equity of 779.74%
   During the past twelve months, the company has given a strong Net Margin of 247.15%
   Tsr Profitability Index - Very Poor Score of 17.50
   Piotroski F Score - Very Poor Value of 1.0
   Very Low Dividend Yield of 0 %
   Negative Net profit for last two years
   In the last three years, the company has given poor Net Margin
   In the last three years, the company has given poor Returns on Equity
   In the last three years, the company has given poor Returns on Assets
   EPS decline for last four quarters
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity 779.74 0 0 % 0
Return On Asset 10.63 -21.41 46.65 % -18.91
Net Profit Margin 247.15 0 0 % 0
Operating Profit Margin -611.15 0 0 % 0
EBITDA Margin -557.04 0 0 % 0


Highlights
Market Cap4966.62 K
Enterprise Value11355.62 K
Price/Book TTM1099.29
Outstanding Share3651.93 K
Float/ Outstanding Share74.49%
Dividend Yield0 %
Share Holding
Guru Numbers
Price/Graham No
Peter Lynch Ratio0
Piotroski F Score1.00
Altman Z Score-6.70
Sloan Ratio0.054
Peter Lynch Fair Value0.203


BVXV - Growth Highlights

Growth Analysis

   Tsr Growth Index - Very Poor Score of 14.42
   Quarterly sales in last 5 Quarter is trending down
   Annual sales in last 3 years is trending down
   Company's Total Assets is Decreasing for last 3 years
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue 2016.00 K 100.00 % 100.00 %
Gross Profit 2016.00 K 100.00 % 100.00 %
EBITDA -11230.00 K 60.72 % 72.02 %
Net Profit 4982.56 K 85.50 % 167.21 %
EPS 0.0096 99.79 % NA


BVXV - Stability Highlights

Stability Analysis

   Paid More Than 50% of Debt, Heading towards debt free
   Debt to equity ratio has decreased and is lowest in last five years
   Cash ratio of 6.02
   Tsr Stability Index - Poor Score of 20.31
   Altman Z Score of -6.70 suggest high risk
   Company is unable to generate enough free cash to support the business.
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio -11.63 -523.74 % -3.33
Cash Ratio 6.02 -19.71 %
Quick Ratio 0 0 % 4.12
Shareholders Equity -6.50 -127.76 %
Debt to EBITDA -1.95 18.62 %


Historical Valuation Ratios of BiondVax Pharmaceuticals Ltd.

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of BiondVax Pharmaceuticals Ltd.

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of BiondVax Pharmaceuticals Ltd.

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of BiondVax Pharmaceuticals Ltd.

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)